Jonathan Aschoff
Stock Analyst at Roth MKM
(0.55)
# 3,921
Out of 4,883 analysts
43
Total ratings
25%
Success rate
-36.34%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $3.13 | +251.44% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $9.41 | +123.17% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $11,100 → $5,920 | $3.04 | +194,636.84% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.59 | +1,032.08% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $17 | $0.22 | +7,644.87% | 2 | Aug 13, 2024 | |
| OTRK Ontrak | Maintains: Buy | $60 → $45 | $0.48 | +9,216.77% | 2 | Aug 9, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.48 | +4,094.63% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $336 → $176 | $0.25 | +70,896.37% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $0.35 | +11,410.79% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $20 → $28 | $4.73 | +491.97% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $7.08 | +408.47% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3,750 → $18,000 | $9.76 | +184,326.23% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.70 | +426.32% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $3.95 | +4,963.29% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.43 | +477.32% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,400 → $7,200 | $0.77 | +934,843.51% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $0.93 | +763.56% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.69 | +3,617.47% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.69 | +57,862.61% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $5.47 | +594.70% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360,000 | $4.94 | +7,293,698.25% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $2.14 | +4,385.98% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.36 | +450.85% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $3.13
Upside: +251.44%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $9.41
Upside: +123.17%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100 → $5,920
Current: $3.04
Upside: +194,636.84%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.59
Upside: +1,032.08%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $17
Current: $0.22
Upside: +7,644.87%
Ontrak
Aug 9, 2024
Maintains: Buy
Price Target: $60 → $45
Current: $0.48
Upside: +9,216.77%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.48
Upside: +4,094.63%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $336 → $176
Current: $0.25
Upside: +70,896.37%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $0.35
Upside: +11,410.79%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $20 → $28
Current: $4.73
Upside: +491.97%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $7.08
Upside: +408.47%
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $9.76
Upside: +184,326.23%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $5.70
Upside: +426.32%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $3.95
Upside: +4,963.29%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.43
Upside: +477.32%
Feb 14, 2023
Maintains: Buy
Price Target: $2,400 → $7,200
Current: $0.77
Upside: +934,843.51%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $0.93
Upside: +763.56%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.69
Upside: +3,617.47%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.69
Upside: +57,862.61%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $5.47
Upside: +594.70%
Feb 12, 2021
Initiates: Buy
Price Target: $360,000
Current: $4.94
Upside: +7,293,698.25%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $2.14
Upside: +4,385.98%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $2.36
Upside: +450.85%